Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).
Sponsor: Merck Sharp & Dohme LLC
Summary
Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults.
Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants.
Key Details
Gender
All
Age Range
18 Years - 30 Years
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2024-12-05
Completion Date
2028-07-17
Last Updated
2026-02-12
Healthy Volunteers
Yes
Conditions
Interventions
V350A
Vaccination administered via intramuscular injection
V350B
Vaccination administered via intramuscular injection
Placebo
Vaccination administered via intramuscular injection
Locations (9)
California Clinical Trials Medical Group managed by PAREXEL ( Site 0011)
Glendale, California, United States
QPS-MRA, LLC ( Site 0012)
Miami, Florida, United States
Alliance for Multispecialty Research, LLC ( Site 0008)
Kansas City, Missouri, United States
Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0016)
Springfield, Missouri, United States
Velocity Clinical Research Lincoln ( Site 0004)
Lincoln, Nebraska, United States
Velocity Clinical Research, Omaha ( Site 0005)
Omaha, Nebraska, United States
Remington-Davis, Inc. ( Site 0017)
Columbus, Ohio, United States
Lynn Health Science Institute ( Site 0010)
Oklahoma City, Oklahoma, United States
Alliance for Multispecialty Research, LLC ( Site 0009)
Knoxville, Tennessee, United States